Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Boston Scientific said a cybersecurity incident detected on August 25 disrupted global operations, including information systems used to process and ship customer orders. The medical-device manufacturer activated incident-response procedures and began working with third-party cybersecurity specialists. Disruptions are expected to
Successful pharmaceutical facilities depend on smart design, reliable utilities, qualified equipment, and strong engineering controls. This guide explains how specialist consultants support GMP-ready projects, reduce compliance risks, strengthen CQV activities, and improve facility performance from design through handover.
USFDA issued a Form 483 with seven inspectional observations to Cipla Limited’s Pithampur manufacturing facility in Madhya Pradesh after a follow-up cGMP inspection from August 17 to August 25, 2026. The outcome renews scrutiny of a site that received eight
The FDA’s proposed PDUFA VIII framework could move manufacturing readiness discussions much earlier in the drug approval process. The plan introduces new CMC facility interactions before submission, stronger communication during inspections and additional engagement after inspection findings. For pharmaceutical sponsors,
Explore current pharmaceutical consultant salary benchmarks across roles, specialties, locations, and employment models. This guide explains how experience, regulatory expertise, GMP knowledge, and contract structure shape earnings, helping life science professionals compare opportunities and plan their next consulting move.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has highlighted a Class 2 recall of one batch of Fingolimod Zentiva 0.5 mg Capsules after shelf-life testing identified a potential risk of metal-particle contamination. Zentiva UK Pharma Limited is recalling
Vitruvias Therapeutics is voluntarily recalling one nationwide lot of Thyroid Tablets, USP 30 mg after testing confirmed potential superpotency. The affected lot 504950 was distributed across the United States between January 31 and September 30, 2025. FDA published the company
Explore how the pharmaceutical supply chain connects GDP controls, cold-chain logistics, serialization, supplier oversight, and shortage prevention. Learn practical strategies to strengthen traceability, reduce distribution risks, and build more resilient, compliant pharmaceutical logistics operations across global networks today.
The FDA has placed Regenxbio’s experimental Hunter syndrome gene therapy RGX-121 on clinical hold after spinal scans identified abnormalities in five study participants. The patients received the treatment about three to six years ago and remain asymptomatic. However, the regulatory
Karnataka authorities are investigating an alleged interstate drug network after officials seized medicines, expired stock, counterfeit labels, packaging materials and an injection-filling unit worth about ₹4.91 crore from an unlicensed facility near Bidadi. The recovered stock included products labelled as